Mis Selling in Insurance

The mis-selling of insurance products within the Middle East and North Africa region represents a significant threat to the long-term viability and reputation of the insurance sector. This issue is not merely a collection of isolated compliance infractions or the actions of a few rogue agents. Instead, it is a systemic governance challenge rooted in the misalignment of distribution incentives, product complexity, and inadequate post-sale verification mechanisms.

Boards must recognize that when short-term premium volume is prioritized over product suitability, the resulting conduct risk directly undermines capital preservation and regulatory standing.

Many boards misread this issue by treating mis-selling as an operational nuisance or a localized sales force problem that can be managed through standard compliance checklists. This perspective overlooks the structural drivers of mis-selling, such as aggressive commission structures, opaque intermediary relationships, and the lack of clear target market definitions. By failing to look past aggregate sales figures, directors remain blind to the underlying customer dissatisfaction, high lapse rates, and potential regulatory interventions that can abruptly halt business operations.

For independent directors and board chairs, the relevance of distribution governance lies in its direct connection to capital allocation and enterprise value. High early-stage lapse rates and policy surrenders represent a direct drain on capital through unrecovered acquisition costs and increased administrative expenses. Furthermore, as regulators across the region intensify their focus on consumer protection and conduct risk, insurers that fail to govern their distribution channels face severe penalties, license suspensions, and irreparable brand damage.

The decision pressure facing boards today is immediate and demanding. Directors must shift from a passive, retrospective review of compliance reports to an active, data-driven oversight of all distribution channels. This transition requires the board to demand granular, transaction-level evidence of product suitability, restructure incentive frameworks to align with policyholder retention, and establish clear lines of executive accountability for customer outcomes.

• Distribution channel economics must be aligned with long-term policyholder retention, as high early-stage lapse rates indicate systemic mis-selling that erodes corporate capital.

• Regulatory expectations in the Middle East and North Africa region are shifting rapidly toward individual executive and board-level accountability for product design and sales practices.

• Opaque commission structures and volume-based incentives for intermediaries create inherent conflicts of interest that management must actively mitigate through structured control frameworks.

• Post-sale customer contact and independent verification processes must be treated as core control metrics rather than administrative tasks, providing early warning signs of conduct risk.

• Product complexity must be matched by precise target market definitions, ensuring that sophisticated investment-linked or long-term savings products are not sold to retail segments lacking financial literacy.

The central thesis of this brief is that mis-selling is a structural governance failure rather than an individual agent behavioral issue. It occurs when a board permits a business model that prioritizes short-term premium volume over long-term policyholder value. When distribution incentives are decoupled from underwriting discipline and customer suitability, the resulting conduct risk inevitably crystallizes as financial and reputational damage.

The board cannot delegate the ethical and financial oversight of distribution to management or third-party intermediaries.

Furthermore, the board must treat distribution governance as an active capital allocation decision. Capital consumed by high lapse rates, remediation programs, and regulatory penalties is capital diverted from strategic growth and technology investment. A sustainable insurance operation requires the board to enforce a zero-tolerance threshold for distribution channels that cannot empirically prove customer suitability.

This requires a fundamental shift in how boards evaluate performance, moving from premium volume metrics to quality-of-earnings and customer retention indicators.

This thesis challenges the traditional view that sales practices are purely operational matters best left to management. In the current regulatory environment, directors must treat distribution conduct as a principal risk, requiring the same level of analytical rigor, independent assurance, and quantitative reporting as actuarial reserves or investment portfolios. Only by establishing rigorous, data-driven oversight can the board protect the insurer's balance sheet and secure its regulatory license to operate.

Boards frequently make the mistake of relying on aggregate complaint volumes as their primary measure of sales conduct. This is a dangerous misread because low complaint volumes do not equate to fair customer outcomes. In many Middle East and North Africa markets, retail policyholders may not understand they have been mis-sold a product until years later when surrender values or claims are realized.

By the time complaints spike, the financial and reputational damage is already systemic and costly to remediate.

Another common misread is the assumption that outsourcing distribution to licensed brokers or bancassurance partners transfers the associated conduct risk. Legally and reputationally, the underwriting insurer remains fully responsible for the outcomes delivered to the end customer. Management often presents high-level assurances of partner compliance, but boards must demand proof that these partners are actively monitored, trained, and held to the same conduct standards as internal sales forces.

Finally, boards often fail to connect distribution practices with capital adequacy. They may celebrate strong premium growth in complex savings or investment-linked products without analyzing the lapse profiles of those same portfolios. If a significant percentage of policies lapse within the first two years, the insurer loses the unamortized acquisition costs, which directly reduces capital reserves.

Boards must require management to prove that growth is profitable and sustainable, rather than a temporary boost to the top line that conceals a long-term capital drain.

The insurance market in the Middle East and North Africa region is characterized by intense competition, low insurance penetration, and a heavy reliance on third-party intermediaries. Independent brokers, individual agents, and bancassurance partnerships dominate the distribution of both life and non-life products. In this environment, insurers face constant pressure to maintain and grow market share, often leading to aggressive sales tactics and a focus on volume over value.

Product complexity has also increased, particularly with the introduction of investment-linked products, complex medical schemes, and multi-layered commercial policies. These products require a high degree of financial literacy to understand, yet they are frequently marketed to retail consumers without adequate disclosure of fees, charges, and surrender penalties. The mismatch between product complexity and customer understanding is a primary driver of mis-selling in the region.

Simultaneously, regional regulators are modernizing their supervisory frameworks. There is a clear shift away from purely prudential regulation toward active conduct-of-business supervision. Regulatory authorities are introducing stricter rules around product governance, disclosure standards, and intermediary commissions.

Insurers are now expected to demonstrate that their products are designed with the customer's best interests in mind and that their distribution channels are subject to rigorous oversight.

The transition to digital distribution channels adds another layer of complexity. While digital platforms offer efficiency, they also introduce new conduct risks, such as pre-ticked boxes, inadequate digital disclosures, and algorithmic bias in product recommendations. Underwriting and claims functions are often disconnected from the distribution feedback loop, meaning that claims rejections due to non-disclosure or misunderstanding of policy terms are not systematically analyzed to identify mis-selling patterns.

Evidence: Intermediary commission structures and incentive schemes across all distribution channels. Why it matters: Opaque or front-loaded commission structures create strong incentives for intermediaries to prioritize sales volume over product suitability and customer retention. Warning sign: A high concentration of commissions paid upfront with no clawback provisions or link to multi-year policy retention.

Evidence: Early-stage lapse and surrender rates analyzed by distribution channel, product line, and individual intermediary. Why it matters: High lapse rates within the first twelve to twenty-four months are a primary indicator of mis-selling, as customers realize the product does not meet their needs or expectations. Warning sign: A sudden spike in lapses or surrenders in a specific channel or product line, particularly after the initial commission payout period.

Evidence: Post-sale welcome call and customer callback completion rates, including detailed response data. Why it matters: Independent post-sale verification calls provide direct evidence of whether the customer understood the product terms, fees, and exclusions before the policy was finalized. Warning sign: Low completion rates for welcome calls or a high percentage of customers expressing confusion about key policy terms during the call.

Evidence: Root-cause analysis of claims rejections based on non-disclosure, policy exclusions, or pre-existing conditions. Why it matters: High rates of claims rejections often stem from poor sales practices where intermediaries fail to properly explain policy exclusions or collect accurate customer information. Warning sign: An increasing trend in claims rejections due to non-disclosure, particularly in retail health and life portfolios.

Evidence: Target market definition documents and actual buyer demographic alignment reports. Why it matters: This evidence proves whether products are being sold to the intended customer segment or are being pushed to unsuitable buyers to meet sales targets. Warning sign: Significant deviations between the approved target market profile and the actual demographic data of policyholders.

Evidence: Compliance monitoring and mystery shopping results for high-risk distribution channels and bancassurance partners. Why it matters: Independent testing of the sales process provides objective evidence of how products are actually being presented and sold to consumers. Warning sign: Repeated compliance failures or poor mystery shopping scores that are not followed by formal remediation or disciplinary action.

Evidence: Internal audit reports on distribution partner oversight, outsourcing controls, and intermediary training programs. Why it matters: This evidence demonstrates whether management has established effective control frameworks over third-party distributors who represent the insurer's brand. Warning sign: Internal audit findings indicating weak oversight, outdated training records, or a lack of formal audits of major distribution partners.

Risk: Regulatory sanction and license restriction due to systemic conduct failures. Board concern: Regulators may impose severe penalties, suspend distribution licenses, or mandate costly retrospective remediation programs that disrupt business operations. Management evidence required: A comprehensive regulatory compliance matrix mapping local conduct requirements to specific internal controls, supported by regular compliance testing reports.

Risk: Capital erosion from high early-stage lapses and unamortized acquisition costs. Board concern: The insurer may fail to recover high upfront acquisition costs, leading to direct write-offs and a reduction in capital reserves. Management evidence required: Actuarial analysis of acquisition cost recovery and lapse experience, showing the financial impact of early surrenders on capital adequacy.

Risk: Reputational damage and loss of institutional investor confidence. Board concern: Public disclosure of mis-selling practices or high customer complaints can damage the insurer's brand, leading to a loss of business and a decline in valuation. Management evidence required: Media monitoring reports, customer satisfaction indices, and investor relations feedback, alongside a documented crisis communication plan.

Risk: Ineffective oversight of third-party intermediaries and bancassurance partners. Board concern: The insurer may be held liable for the non-compliant sales practices of external partners who are not subject to adequate control or monitoring. Management evidence required: Standardized distribution agreements containing clear conduct clauses, right-to-audit provisions, and evidence of regular partner audits.

Risk: Product design flaws leading to unintended customer outcomes and litigation. Board concern: Complex products with opaque fee structures or restrictive terms may lead to widespread customer detriment and subsequent class-action litigation. Management evidence required: Minutes and approval documents from the product governance committee, demonstrating rigorous testing of product features and customer understanding.

Risk: Data integrity failures in distribution and sales reporting. Board concern: Management may rely on inaccurate or incomplete data to assess sales performance and conduct risk, leading to flawed decision-making. Management evidence required: Data quality assessment reports and internal audit validation of the key performance indicators used in board reporting.

The strategic implications of distribution governance extend to the core of the insurer's business model and capital allocation strategy. Boards must recognize that continuing to rely on high-volume, high-commission distribution channels that generate poor customer outcomes is strategically unsustainable. While these channels may deliver short-term premium growth, they ultimately destroy enterprise value through high lapse rates, regulatory penalties, and increased operational costs.

The board must be prepared to make explicit trade-offs, potentially accepting lower short-term growth in exchange for higher-quality, more resilient earnings.

This strategic shift requires a reevaluation of the insurer's operating model. The traditional separation between sales, underwriting, and compliance must be dismantled. Product design, distribution, and post-sale monitoring must be integrated into a single, continuous feedback loop.

This integration ensures that insights from claims rejections, customer complaints, and lapse rates are immediately used to refine product features and distribution controls. The operating model must also prioritize investment in technology that enables real-time monitoring of sales practices and automated post-sale verification.

Furthermore, the insurer's regulatory posture must evolve from reactive compliance to proactive engagement. By demonstrating a commitment to robust distribution governance and fair customer outcomes, the insurer can build trust with regional regulators. This trust can be a significant competitive advantage, enabling smoother product approvals, lower regulatory capital charges, and a stronger position in the market.

Ultimately, a reputation for fair dealing and customer-centric distribution enhances enterprise value and attracts long-term institutional investors who prioritize sustainable governance.

• Restructure intermediary compensation models to defer a significant portion of commissions over the policy lifecycle, linking payouts directly to multi-year retention rates.

• Implement mandatory post-sale verification calls for all high-value or complex retail products, conducted by an independent internal team before policy issuance.

• Establish a formal product governance committee with veto power over product launches that lack clear target market definitions or objective suitability criteria.

• Conduct regular, independent mystery shopping exercises across all distribution channels, including bancassurance partners and independent brokers, to test sales practices.

• Integrate claims rejection data and customer complaint root-cause analysis into the quarterly product review process to identify and remediate systemic mis-selling indicators.

• Terminate distribution agreements with intermediaries who consistently exceed established thresholds for early-stage lapses, customer complaints, or non-compliance.

The board must exercise independent judgment to recognize that sustainable profitability cannot be built on a foundation of poor customer outcomes. Directors must reject the notion that mis-selling is an inevitable cost of doing business in competitive markets. The long-term viability of the insurer depends on its ability to deliver genuine value to policyholders, and the board must hold management strictly accountable for achieving this objective.

To enforce this standard, the board must establish a clear decision requirement: any distribution channel or product line that fails to meet defined retention and suitability benchmarks within a specified timeframe must be suspended or restructured. This requirement must be non-negotiable, regardless of the short-term impact on premium volume or market share. The board must prioritize capital preservation and regulatory credibility over temporary growth targets.

Ultimately, the board must not accept narrative assurances from management that customer satisfaction is high based solely on low complaint volumes or rising premium sales. Directors must demand empirical, auditable data proving that products are understood by, suitable for, and delivering value to the policyholders who purchase them. If management cannot provide this evidence, the board must assume that conduct risk is unmanaged and take immediate corrective action.